Ixico Plc (IXI) New Ord GBP0.01

Sell:9.50pBuy:10.00pNo change

Prices delayed by at least 15 minutes
Sell:9.50p
Buy:10.00p
Change:No change
Prices delayed by at least 15 minutes
Sell:9.50p
Buy:10.00p
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

Key people

Bram Goorden
Chief Executive Officer
Grant Robert Nash
Chief Financial Officer, Executive Director, Company Secretary
Mark Robert Warne
Non-Executive Chairman of the Board
Katherine Jane Rogers
Non-Executive Director
Dipti Amin
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    IXI
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00BFXR4C20
  • Market cap
    £9.04m
  • Employees
    81
  • Shares in issue
    92.67m
  • Exchange
    London Stock Exchange (LON)
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.